Thursday, November 21, 2024
11/21/2024
Project Summary/Abstract: CFD Research Corporation has developed a novel microbiome-balancing wet wrap therapy for atopic dermatitis based on a natural compound with unique physicochemical and pharmacological activities. The compound has been found to have an interleukin-based immune modulatory effect that helps soothe the flare- up of eczema, and it is highly selective to the pathogen Staphylococcus aureus while being gentle to the skin microbiome, including beneficial bacteria such as Roseomonas mucosa and Corynebacterium tuberculostearicum. The compound was incorporated into cellulose-based fabrics such as rayon and cotton to create a controlled-release wet wrap/bandage which will be tested on mouse models of eczema. The technology has the potential become a standard of care for treating eczema patients and decrease or eliminate the use of steroid ointments in controlling atopic dermatitis in children and adult populations.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
